GENERATION HD1

A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST HUNTINGTON’S DISEASE

Terminated

ABOUT

SPONSOR

Hoffmann-La Roche

PARTICIPANTS

909

Generation HD1 is a Phase III trial where Huntington’s disease patients get injections in the spine with a drug called Tominersen (previously called RG6042). The drug is aiming to lower the amount of Huntingtin protein in brain cells. Some of the participants get the active drug injected every 2nd months, another group gets the active drug every 4 months and a third group gets injected with a placebo drug. The potential effect of the study will be measured by testing cognitive, motor and social functioning.

Estimated Study Completion Date: 9 July, 2022


UPDATES

Roche provides update on tominersen programme in manifest Huntington’s disease

Dosing to stop in Phase III clinical study of tominersen following recommendation from an Independent Data Monitoring Committee (iDMC)

More info here

AUSTRIA

DENMARK

FRANCE

GERMANY

ITALY

NETHERLANDS

RUSSIA

SPAIN

SWITZERLAND

UNITED KINGDOM